Criticism mounting on Express Scripts merger
Congressional opposition continues to grow to the proposed $29.1 billion merger between pharmacy benefit managers Express Scripts Inc. and Medco Health Solutions, which is being reviewed by the FTC.
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch